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ABSTRACT 
Thirty six consecutive patients with primary sclerosing cholangitis (PSC), 20 males 
median age 42 years, were studied in order to define prognostic variables and 
determine the influence of surgery on outcome. Presentation was usually with insidious 
cholestasis or recurrent cholangitis. Twenty six patients (72 per cent) had associated 
inflammatory bowel disease (ulcerative colitis 20, Crohn's disease 2, unclassified 4). 
Thirty two patients were followed prospectively for up to nine years. Twenty three 
remained either stable or had slowly progressive disease. Of the remaining nine 
patients, seven died (five from end-stage liver failure and two from 
cholangiocarcinoma) and two patients underwent liver transplantation. Actuarial 
survival at five years was 52 per cent. A raised serum bilirubin concentration was the 
only variable at presentation that independently predicted a poor outcome. 
Cholangiograms were available for detailed assessment in thirty PSC patients. Neither 
the extent of biliary involvement nor the presence of surgical correctable ("dominant") 
strictures in the extrahepatic ductal system were of prognostic importance. Six patients 
who developed obstructive jaundice associated with advanced liver disease underwent 
surgical drainage operations for dominant biliary strictures, but this did not seem to 
prevent progression of the disease. Two patients who progressed to end-stage liver 
disease went on to liver transplantation and were alive with functioning grafts at seven 
and fourteen months respectively. Nine patients with asymptomatic PSC were followed 
prospectively for up to twelve years. None of these patients developed overt liver 
disease but serum bilirubin levels became mildly elevated in two patients. It is 
concluded that symptomatic PSC is a progressive disease with a poor prognosis. 
Patients with advanced liver disease due to PSC should be considered directly for liver 
transplantation. In contrast, asymptomatic PSC patients may remain symptom-free for 
many years. 
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Figure 1.2 Liver biopsy specimen in a patient with primary sclerosing cholangitis 
showing a portal tract with dense periductal fibrosis which has resulted in 
disappearance of the portal bile duct. Fibrosis has extended beyond the 
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bile ducts. (page 47) 
Figure 6.1 ERC of case 1 demonstrating marked irregularity of the intrahepatic bile 
ducts suggestive of primary sclerosing cholangitis. (page 58) 
Figure 6.2 ERC of case 3 demonstrating diffuse narrowing and irregularity of the 
intrahepatic bile ducts with involvement of the hepatic duct bifurcation. 
The extrahepatic duct was however not involved. (page 59) 
Table 6.1 Clinical details of 11 cases of malignant obstuctive cholangiopathy 
mimicking primary sclerosing cholangitis. (page 60) 
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CHAYfER 1: THE SYNDROME OF PRIMARY SCLEROSING CHOLANGITIS 
1.1. Introduction 
Primary sclerosing cholangitis (PSC) is a syndrome of unknown aetiology characterised 
by chronic fibrosing inflammation of the intra- and extrahepatic bile ducts. PSC is 
strongly associated with inflammatory bowel disease (IBD), especially ulcerative colitis 
(UC). 1-3 Previously considered to be a rare disease, PSC has been diagnosed much 
more frequently with improvements in imaging and particularly since the advent of 
endoscopic retrograde cholangiopancreatography (ERCP). The natural history of PSC 
is unpredictable although progression seems to occur in most patients. Medical therapy 
is unsatisfactory and end-stage liver disease due to PSC is often the reason for liver 
transplantation. 4 Accordingly, there has been a remarkable upsurge of interest in all 
aspects of this chronic liver disease during the past decade. 
1.2. Clinical manifestations 
PSC occurs primarily in young men. Seventy per cent of patients are male, and more 
than two thirds are under 45 years of age at the time of diagnosis. 1-3 The disorder 
usually begins insidiously with progressive fatigue, pruritus and jaundice. Bacterial 
cholangitis is an unusual presenting symptom of PSC, but frequently occurs in those 
PSC patients who have previously undergone biliary surgery or who have developed 
obstructing dominant strictures of the large bile ducts. Some patients with PSC may 
have no symptoms, and a persistly raised alkaline phosphatase is the only abnormality 
noted on clinical examination and routine biochemical investigations. Patients may also 
present initially with advanced disease that is manifested by haemorrhage from 
oesophageal varices, ascites, or hepatic encephalopathy. 
Although the physical examination may be normal, most patients have some 
abnormality, most commonly hepatomegaly, jaundice, or splenomegaly. Patients with 
longstanding disease show evidence of chronic cholestasis, such as deep jaundice, 
hyperpigmentation, xanthelasmata, scratch marks, bruising, weight loss and 
steatorrhoea. 
A cholestatic biochemical profile is present in all patients with PSC. Although the 
serum level of alkaline phosphatase may fluctuate, it is always raised, often markedly 
so. Most patients have a mild increase in the level of serum aspartate transaminase. 
Bilirubin values are usually raised in symptomatic patients. There are no consistently 
abnormal serologic markers in the serum. Tests for antimitochondrial antibody, 
rheumatoid factor, smooth-muscle antibody, and antinuclear antibody are negative in 
more than 90 per cent of patients. 1 Tests related to copper metabolism, such as hepatic 
copper concentrations and serum caeruloplasmin levels, are abnormal in most patients 
with PSC as a consequence of cholestasis. 
1.3. Radiology 
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Cholangiography, usually obtained by ERCP, is the key diagnostic investigation in 
patients with PSC. Endoscopic cannulation of the common bile duct may be difficult 
or impossible due to papillary fibrosis5 At duodenoscopy, the papilla may appear to 
be retracted ("tented up"), presumably as a result of fibrotic shortening of the common 
bile duct (author's observation). Considerable resistance may be felt as radiographic 
contrast material is injected into the narrowed biliary tree. In order to obtain adequate 
detail of the intrahepatic ducts, the catheter should be advanced deeply into the 
common bile duct to a position above the cystic duct, and it may be necessary to use a 
balloon occlusion technique when injecting contrast. 5 Cholangiography in patients with 
PSC carries a significant risk of bacterial cholangitis. Thus, strict endoscopic 
disinfection procedures should be followed, and ERCP examinations should be 
performed under antibiotic cover. Furthermore, radiographic contrast should only be 
introduced above dominant biliary strictures if facilities are available to facilitate 
further biliary drainage. 6 
The radiologic appearances of PSC are characteristic. 7 The intrahepatic and 
extrahepatic bile ducts are involved to a variable degree, with multiple strictures and 
areas of relative dilatation, producing a "beaded appearance" (Figure 1.1). These 
cholangiographic changes are not specific for PSC, however, and the diagnosis of PSC 
remains one of exclusion. The commonest causes of "secondary sclerosing cholangitis" 
are longstanding choledocholithiasisis and post-operative stricture with complicating 
recurrent bacterial cholangitis. 1 Diffuse malignant hepatobiliary infiltration may 
produce narrowing and deformity of bile ducts, seen at cholangiography. However, 
multifocal strictures and extrahepatic duct involvement are not a feature of malignant 
cholangiopathy (see Chapter 6). HIV-associated cholangiopathy may produce a 
cholangiographic picture virtually identical to PSC ("AIDS sclerosing cholangitis"). 
Cholangiograhic features suggestive of HIV-associated cholangiopathy include papillary 
stenosis and long extrahepatic bile duct strictures. 8 These apearances may be the result 
of recurrent biliary infection with cryptosporidium or cytomegalovirus in AIDS 
patients, or alternatively due to direct infection of the biliary epithelium with HIV. 8 
3 
1.4. Hepatobiliary pathology 
Although some histological lesions on liver biopsy are very suggestive of PSC, there 
are no absolutely unique features. The prime role of the histopathologist is to exclude 
other diseases and confirm that the changes present are consistent with PSC, rather than 
provide an unequivocal diagnosis. PSC can affect all sizes of bile ducts, from the 
smallest interlobular ducts to the common bile duct. 9 The fibro-obliterative ductal 
lesion is most characteristic of PSC (Figure 1.2), but is only found in 10 to 50 per cent 
of cases. 10 The interlobular ducts (less than lOOµm diameter) are involved, and show 
periductal concentric fibrosis ("onion skinning") with a sparse mononuclear 
inflammatory infiltrate. Biliary epithelial atrophy results, and eventually the lumen is 
obliterated by fibrous tissue to form a nodular fibrous scar. Another characteristic 
feature is ductopaenia ("vanishing bile ducts"). Reduction of bile duct numbers is 
determined by correlating the number of interlobular bile ducts with hepatic arteries in 
the portal tracts. There is normally one bile duct to each hepatic artery and reduction 
of this ratio indicates bile duct loss. 9 Ductopaenia may however also be seen in 
primary biliary cirrhosis, graft versus host disease, chronic rejection, and adulthood 
idiopathic ductopaenia. 9 Saccular dilatation of septal bile ducts ( ducts greater than 
lOOµm diameter and lined with tall columnar epithelium) may occur. This 
cholangiectasia may occur in the absence of proximal stenosis and is thought to be part 
of the PSC pathogenic process. 11 A variety of nonspecific histological changes are 
commonly seen seen in PSC livers, including bile stasis, bile ductular proliferation and 
portal inflammation. 9 
The main differential diagnosis on liver biopsy is primary biliary cirrhosis (PBC), 
another condition showing bile duct damage and loss. 12 The inappropriate 
accumulation of copper-associated protein and the relative absence of Mallory bodies 
and of periductal granulomas favour PSC rather than PBC. Also in the hepatic 
histologic differential diagnosis is large extrahepatic bile duct obstruction, which 
produces a histological picture of swollen portal tracts with a neutrophil infiltrate and 
bile lakes. There may be fibrin deposition, periductal fibrosis and ductular 
proliferation. 13 Histology of the large extrahepatic ducts in PSC is nondiagnostic, and 
typically reveals generalised chronic inflammation and fibrosis. 
A staging system analogous to that for PBC has been developed for PSC based on 
presumed pathological progression of the disease. 14 Stage 1 (portal) shows few duct 
lesions, portal inflammation and oedema; stage 2 (periportal) shows widespread duct 
lesions and portal tract expansion due to piecemeal necrosis and periportal fibrosis; 
stage 3 (septal) shows bridging fibrosis; and stage 4 shows biliary cirrhosis. However, 
the disease is characteristically focal and appearances may vary greatly in different 
parts of the same liver and even in the same biopsy specimen, thus limiting the 
usefulness of histological staging. 9 
1.5. Inflammatory bowel disease 
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There is a close association between PSC and inflammatory bowel disease, especially 
ulcerative colitis (UC). Approximately 70 per cent of all patients with PSC have 
coexisting UC, 3 and PSC is the most common form of chronic liver disease found in 
UC, occurring in 3 - 10 per cent of patients. 15 Paradoxically, the colitis is usually total 
but symptomatically mild, sometimes virtually asymptomatic. Although the symptoms 
of UC usually develop before those of PSC, in some patients the onset of PSC may 
precede the symptoms of colitis by a number of years. The natural history of the 
hepatobiliary disease is completely unrelated to the activity, severity, or clinical course 
of the colitis. Interestingly, panproctocolectomy has no influence on the clinical 
progression or mortality of patients with PSC. 16 PSC has been reported in patients 
with Crohn' s disease with colonic involvement, but the association is uncommon. 17 
1.6. Cholangiocarcinoma 
There is a strong association between PSC and cholangiocarcinoma. 
Cholangiocarcinoma may arise in 10 - 15 per cent of patients with pre-existing PSC 
and can also present in a synchronous fashion with PSC. 18 PSC patients who appear to 
be at highest risk for developing cholangiocarcinoma are those with long-standing UC 
and cirrhotic stage PSC on liver biopsy. 18 PSC may thus be considered to be a 
premalignant condition of the biliary tree. Rapid clinical deterioration in a patient with 
PSC should alert the clinician to a possible complicating cholangiocarcinoma. 
Cholangiograpic features suggestive of cholangiocarcinoma include major sequential 
changes and impressive duct dilatation. 19 Unfortunately the cholangiographic 
appearances are nonspecific in many patients. Therefore, in all patients with suspicious 
dominant biliary strictures, brush cytology specimens should be taken at ERCP. 
Negative cytology is unhelpful, however, and repeat samples should be obtained from 
suspicious lesions. Early diagnosis is thus difficult, and approximately 10 per cent of 
PSC patients undergoing liver transplantation are found to have an unsuspected 
cholangiocarcinoma. 20 The known association of UC and bile duct cancer (estimated 
prevalence of 5 % ) may be related to underlying PSC. 
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1. 7. Aetiology 
The cause of PSC is unknown, but any hypothesis must explain the clinical associations 
with UC. A number of mechanisms have been postulated, including the absorption of 
toxic substances across the inflamed colonic mucosa, portal bacteraemia, and the 
increased permeation of toxic bacterial products or toxic bile acids through the inflamed 
colon. 21 However, there is no evidence in favour of these hypotheses. Although 
several viruses have been suggested as being implicated in the development of PSC, 
there is no direct evidence for viral infection. 22 
Recent studies suggest that genetic and immunological factors may be important. Three 
sets of siblings from three families have been reported with PSC and UC. 23 PSC is 
closely associated with the HLA B8 and DR3 antigens, which have also been associated 
with other auto-immune diseases, particularly immune chronic active hepatitis and 
coeliac disease. 24 These findings were extended by a recent report that 100 per cent of 
twenty nine PSC patients referred for hepatic transplantation possessed the HLA 
DRw52a antigen , which is on the DR B3 chain. 25 Although the 100 per cent 
association has not been confirmed by other workers , HLA DRw52a does appear to be 
most closely related to the susceptibility to develop PSC. A number of humoral and 
cellular abnormalities have been demonstrated in patients with PSC. Humoral 
abnormalities include the presence of circulating anti-colon and neutrophil cytoplasmic 
antibodies. 26 Several antigens appear to be common to both the colon and the biliary 
epithelium and it is possible that antibodies to these shared epitopes may be of 
importance in the disease pathogenesis. 27 PSC patients have elevated levels of immune 
complexes, which also appear to be poorly cleared by the reticuloendothelial 
system. 28•29 Moreover, there is evidence for classical complement pathway 
activation. 30 The cellular immune abnormalities include a decrease in suppressor T 
cells in peripheral blood with increased numbers of helper and suppressor cells in the 
portal tracts of PSC patients. 31 •32 This finding is in keeping with the demonstration of 
the expression of HLA DR antigens on the biliary epithelial cells. 33 This aberrant 
expression of class II HLA antigens may enable biliary epithelial cells to present 
antigen to the periportal lymphocytes with subsequent activation and differentiation. 
6 
1.8. Medical therapy 
Medical therapy of PSC remains unsatisfactory, and is largely aimed at relief of 
symptoms resulting from chronic cholestasis and treatment of complications. 34 A 
variety of therapies have been utilised to treat pruritus, including cholestyramine, 
activated charcoal, phenobarbitol, rifampicin, plasmapheresis, charcoal 
haemoperfusion, and ultraviolet light. Steatorrhoea should be treated with a low fat 
(40g per day) diet together with supplements of medium chain triglycerides. Fat 
soluble vitamin deficiencies should be identified and corrected by parenteral 
administration, where necessary. Complications of portal hypertension, such as 
bleeding oesophageal varices, ascites and hepatic encephalopathy, are managed in the 
usual manner. Complications specific to PSC include recurrent bacterial cholangitis, 
development of an obstructing dominant stricture of the biliary tract, and 
cholangiocarcinoma. 
A variety of therapies have been tried in order to halt the progression of PSC, including 
D-penicillamine, corticosteroids, and cytotoxic agents. 35-37 However, most trials have 
been uncontrolled, and none of these treatments have been shown to be effective. 
Systemic steroid therapy may be associated with enhanced bone loss in PSC patients 
leading to an increased risk of developing compression fracture of the spine. 38 Topical 
steroids administered as a nasobiliary lavage may induce a higher incidence of bacterial 
cholangitis. 39 More recently there has been enthusiasm for the use of ursodeoxycholic 
acid and methotrexate. The rationale for using ursodeoxycholic acid in the treatment of 
chronic cholestatic liver disease including PSC is the replacement of the bile acid pool 
with a less toxic bile acid. 34 Two recent controlled clinical trials however showed that 
ursodeoxycholic acid therapy in PSC was associated with only minor improvement in 
liver function tests and no improvement in symptoms, liver histology or 
cholangiography. 40•41 In a controlled clinical trial, methotrexate was shown to 
significantly reduce serum levels of alkaline phosphatase but did not have a significant 
effect on serum levels of bilirubin, aminotransferases, or albumin.42 The long-term 
effects of methotrexate on liver disease progression remains unknown. Of concern is 
the inherent hepatotoxicity leading to hepatic fibrosis that is associated with 
methotrexate therapy. 43 As bile duct loss is probably irreversible, any potentially 
effective therapy for PSC must be initiated early in the course of the disease. 
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Figure 1.1 ERC in a patient with primary sclerosing cholangitis showing multiple 
strictures involving intra- and extrahepatic bile ducts with intervening 
dilated segments ("beaded appearance"). 
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Figure 1.2 Liver biopsy specimen in a patient with primary sclerosing cholangitis 
showing a portal tract with dense periductal fibrosis which has resulted 
in disappearance of the portal bile duct (arrow). Fibrosis has extended 
beyond the portal tract to involve the hepatic parenchyma 
(Haematoxylin and eosin). 
CHAPTER 2: NATURAL HISTORY AND PROGNOSTIC INDICES 
IN PRIMARY SCLEROSING CHOLANGITIS 
2.1. Introduction 
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The presentation and course of patients with primary sclerosing cholangitis (PSC) are 
highly variable and unpredictable. Nevertheless, in most symptomatic patients, 
progression appears relentless with the development of jaundice, recurrent biliary 
sepsis, cirrhosis, portal hypertension, and liver synthetic failure. 1-3 With the advent of 
liver transplantation, it has become important to identify prognostic indices to predict 
the risk of progression to liver failure and death. These indices would be useful in 
deriving survival models which could be used to identify individual PSC patients at 
low, moderate, and high risk. A number of such prognostic models have been 
proposed·4-6 Unfortunately, the studies from different units have provided conflicting 
results. In this chapter, the clinical presentation and outcome of 36 consecutive 
patients with PSC seen in Cape Town are described, with the formulation of local 
prognostic indices. 
2.2. Patients and methods 
Between January 1981 and December 1991 thirty six patients with PSC were seen and 
fully documented at the Liver, Gastrointestinal, and Biliary Clinics at Groote Schuur 
Hospital, Cape Town. The diagnosis was based on cholangiographic findings of 
multiple strictures of the bile ducts together with compatible clinical and biochemical 
features. Liver biopsy specimens were examined, and other causes of multiple bile 
duct strictures were excluded. 
The time of diagnosis was defined as the date of the first cholangiogram. Symptoms 
attributable to PSC included fatigue, pruritus, jaundice, right upper quandrant pain, 
fever, and weight loss. Complications included portal hypertension, bleeding varices, 
ascites, encephalopathy, and cholangiocarcinoma. Some patients had no symptoms that 
could be ascribed to their liver disease; the diagnosis of PSC was made on 
cholangiography, which was done because of abnormal biochemical findings in patients 
with inflammatory bowel disease (IBD). 
Liver biopsy specimens from 18 patients were reviewed without knowledge of the 
clinical and cholangiographic findings. The histological stage of the disease was 
recorded according to established criteria: 7 stage 1, cholangitis or portal hepatitis; 
stage 2, periportal fibrosis, piecemeal necrosis, periductal fibrosis, atrophy or 
disappearance of bile ducts; stage 3, septal fibrosis or bridging necrosis, together with 
the features of stage 2; and stage 4, biliary cirrhosis. In addition a histological 
numerical score was devised using a system similar to that for chronic active hepatitis8. 
The following histological variables were assessed: paucity of ducts, periductal fibrosis, 
piecemeal necrosis, cholestasis, periportal inflammation, and scarring. Scoring was as 
follows: 0, absent; 1, mild; 2, moderate; 3, severe. Biliary cirrhosis was either absent 
(0) or present (1). 
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Long term follow-up data were available for 32 patients, the other four having been 
lost to local follow up due to distance of residence. The starting time for all survival 
analyses was the date of the cholangiogram with confirmation of diagnosis. Patient 
outcome was defined as either "good" or "poor". Patients with a good outcome had 
stable or slowly progressive disease, while those with a poor outcome had reached the 
end-point of either death or liver transplantation. 
Presenting features were compared by Student's 't' test and Fisher's exact test. Overall 
actuarial survival was calculated by the Kaplan-Meier method. Prognostic indices were 
derived from univariate and multivariate analyses (Cox's survival analysis with 
correlates) using BMDP software (BMDP Statistical Software, Inc., Los Angeles, 
California, USA) on a mainframe computer. 
2.3. Results 
2.3.1. Clinical features 
The clinical features at presentation of the thirty six patients are shown in Table 2.1. 
Twenty patients were male, and median age was 42 years (range 13-65 years). The 
median duration of symptoms was 14 months (range 1-84 months) before diagnosis. 
The commonest presenting symptoms were jaundice (67 per cent), fatigue (58 per 
cent), and pruritus (53 per cent). Seven patients were asymptomatic at presentation (19 
per cent). Hepatomegaly was recorded in 78 per cent of patients at presentation with 
splenomegaly in 36 per cent. Six patients had other medical conditions - seronegative 
arthritis, scleroderma, immune haemolytic anaemia, pancreatitis, pyoderma 
gangrenosum, and hypothyroidism. 
2.3.2. Inflammatory bowel disease 
Twenty six patients (72 per cent) had associated IBD (Table 2.2). Twenty patients had 
ulcerative colitis, two had Crohn' s disease, and four patients had unclassified colitis. 
Symptoms of IBD preceded the diagnosis of PSC by a median duration of eight years 
(range 43 years before -2 years after diagnosis of PSC). In the patients with ulcerative 
colitis, the colitis was extensive (i.e. total or subtotal) in eighteen. The colitis was 
symptomatically mild (quiescent or medical control) in sixteen patients; four patients 
required colectomy. 
2.3.3. Hepatic histology 
Adequate liver biopsy specimens were available for detailed assessment in 18 patients. 
Histological staging was as follows: stage 1 (n=l), stage 2 (n=4), stage 3 (n=6), and 
stage 4 (n=7). Results of numerical scoring were as follows: score 0-4 (n=2), score 
5-8 (n=O), score 9-11 (n=7), score 12-14 (n=8), and score 15-19 (n=l). 
2.3.4. Subsequent follow-up 
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Adequate follow-up data were available for 32 patients (Table 2.1), the mean duration 
being four years (range 0.4 to 9 years). Twenty three patients either remained stable or 
had slowly progressive disease. Seven patients died (two from cholangiocarcinoma) 
and two patients underwent orthotopic liver transplantation, both of whom were alive 
with functioning grafts after seven and 14 months, respectively. The actuarial survival 
was 52 per cent at 5years (Figure 2.1). 
2.3.5. Prognostic indices 
Twenty three patients with a good outcome (stable or slowly progressive disease) were 
compared with nine patients with a poor outcome ( death or liver transplant) (Table 
2.3). Univariate analysis showed that the following variables at presentation were 
associated with a poor prognosis: raised serum bilirubin concentration, low serum 
albumin concentration, prolonged prothrombin time, presence of ascites, and stage 4 
hepatic histology or with a score of greater than 11. Cox's regression (multivariate) 
analysis showed that a raised serum bilirubin concentration at presentation was the only 
variable that correlated independently with a poor prognosis. 
2.4. Discussion 
During the past decade, PSC has been studied intensively and a much better 
understanding of this syndrome has been gained, particularly in respect to its diagnostic 
features and natural history. 1-6 Most studies suggest an overall poor prognosis for 
patients with a diagnosis of PSC. The five year actuarial surval of 52 per cent of PSC 
patients seen in Cape Town is consistent with survival reported from other centres. 2-6 
It is however the variability in the natural history on the one hand and the extremes in 
the treatment options (varying from conservative treatment to liver transplantation) on 
the other, which compounds management strategy. Therefore, various attempts have 
been made to identify prognostic factors which would hopefully give guidance in the 
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treatment of the individual patient. Several studies have used multivariate analysis to 
develop prognostic survival indices for PSC. This statistical procedure permits 
multiple clinical variables to be analysed simultaneously. 9 Helzberg et al. 10 showed 
that hepatomegaly and raised serum bilirubin concentrations were independent variables 
predictive of a poor outcome. Wiesner et al. 4 found that age, serum bilirubin 
concentration, haemoglobin level, hepatic histological stage, and the presence of 
inflammatory bowel disease were independent predictors of a poor outcome. Herrman 
et al. 6 identified age, serum bilirubin concentration, and the site of biliary involvement 
as indicators of poor prognosis. In patients seen in Cape Town a raised serum bilirubin 
concentration at presentation was the only variable that independently predicted a poor 
outcome, and serum bilirubin is clearly the most weighted variable. Indeed, serum 
bilirubin levels alone could be used as a poor man's prognostic index for PSC 
patients. 11 The divergent results for other prognostic indices can be explained by small 
patient numbers in each reported series. 
Most recently, a multicentre study comprising 426 patients identified serum bilirubin, 
histological stage, age, and splenomegaly as independent prognostic indicators of a 
poor outcome in PSC· 12 This model was assessed by applying methods of statistical 
cross-validation and quantifying the model's reliability by estimating confidence 
intervals for predicting survival probabilities. A formula for the calculation of risk 
scores for the individual patient was devised by combining the values of the four 
prognostic variables with their regression coefficients. A higher score denoted a worse 
prognosis. 
The development of multivariate statistical models in PSC is a major step in identifying 
individual patients at low, medium, and high risk of dying from liver disease. Such 
survival models may be useful for patient counselling, and also for patient stratification 
prior to entry into trials of drugs designed to halt disease progression. Their major 
application however is in recipient selection and timing of liver transplantation for PSC 
patients. 11 Although this represents a major advance, there are pitfalls with current 
survival models. They do not take into account the patient's quality of life, clearly a 
critical factor in the decision for transplantation candidacy in this and other cholestatic 
syndromes. 13 Furthermore, these models cannot forecast life-threatening events, such 
as a major variceal bleed or the unpredictable development of cholangiocarcinoma. 
Therefore, the decision and timing of therapeutic intervention with liver transplantation 
in PSC requires sound and individualised clinical judgement. 
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Table 2.1 Clinical features at presentation and outcome of 36 patients with 
primary sclerosing cholangitis. Figures are number(%) of patients 
unless otherwise stated 
Clinical features (n = 36): 
Male:Female ratio 
Median age (yr) 
Range 
Median duration of symptoms (mo) 
Range 
Jaundice 
Fatigue 
Pruritus 
RUQ pain* 
Weight loss 
Fever ("cholangitis") 
Hepatomegaly 
Splenomegaly 
Asymptomatic 
Outcome (n = 32): 
Median follow-up (yrs) 
Range 
Stable or slowly progressive disease 
Transplant 
Death 
*RUQ, right upper quadrant 
-It- Two patients died with cholangiocarcinoma 
20:16 
42 
13 - 65 
14 
1 - 84 
24(67) 
21(58) 
19(53) 
14(39) 
14(39) 
6(17) 
28(78) 
13(36) 
7(19) 
4 
0.4 - 9 
23 
2 
7--/t-
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Table 2.2 Associated inflammatory bowel disease. Figures are numbers of 
patients (%) unless otherwise stated. 
Ulcerative colitis 20(77) 
Crohn' s disease 2(8) 
Unclassified 4(16) 
Median duration of IBD at time of 
diagnosis of PSC (years) 8 
Range -43years to +2 years 
Extent of ulcerative colitis 
Total 13(65) 
s~~tal 5~~ 
Distal 2(11) 
Activity of ulcerative colitis 
Quiescent 8( 40) 
Medical control 8(42) 
Colectomy 4(21) 
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Table 2.3 Comparison of "good outcome" group with "poor outcome" group. 
Figures are either numbers of patients or mean (SEM). 
Good outcome Poor outcome p value 
(n=23) (n=9) 
Age (years) 39(3.3) 35(3.9) 
Male: female 13:10 3:6 
Inflammatory bowel 
disease 19 4 
Duration of symptoms 
(months) 11(1-84) 8(1-60) 
Bilirubin (µmoll 1) 39(8.8) 164(59) <0.003 
Albumin (g/1) 39(1.2) 32(2.7) <0.02 
INR 1.1(0.2) 1.3(.01) <0.02 
Ascites 2 4 <0.04 
Liver histology 
stage 4 2/11 5/7 <0.02 
score > 11 3/11 6/7 <0.03 
CHAPTER 3: CHOLANGIOGRAPHIC FEATURES OF PRIMARY 
SCLEROSING CHOLANGITIS 
3.1. Introduction 
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Cholangiography is the the key diagnostic investigation in patients with primary 
sclerosing cholangitis (PSC). The characteristic radiologic findings are multifocal 
strictures involving the intra- and extrahepatic bile ducts with areas of relative 
dilatation. 1•2 Cholangiocarcinoma is the most difficult diagnosis to differentiate from 
PSC, and the two conditions may co-exist. 3 In contrast to its important role in 
diagnosis, the value of cholangiography in determining prognosis in PSC is less certain. 
In this study the cholangiograms of thirty PSC patients were studied. The pattern and 
severity of cholangiographic abnormalities were correlated with patient outcome, with 
particular reference to the presence or absence of dominant strictures involving the 
extrahepatic biliary system. 
3.2. Methods 
The cholangiograms of 30 PSC patients were reviewed in a blinded fashion without 
access to the names and clinical details of the patients. The distribution and site(s) of 
predominant bile duct involvement were recorded and scored as follows: 0, not 
involved; 1, minimal involvement; 2, moderate involvement; 3, severe involvement; 
and 4, non-filling. Cholangiograms were assessed for the presence of a dominant 
stricture at the hepatic bifurcation, common hepatic duct, or common bile duct. A 
"dominant" stricture was defined as a stricture which was thought to be clinically 
significant (i.e. potentially surgical correctable) and not necessarily the most severe 
biliary stricture (Figure 3.1). Additional features that were recorded included 
distortion ("pulling up") of the pancreatic duct (Figure 3 .1), presence of a biliary 
stricture at the site of entry of cystic duct, side of entry of the cystic duct into the 
common bile duct, and features suggestive of cholangiocarcinoma. The 
cholangiographic findings in twenty patients from the "good outcome" group were 
compared with those in seven patients from the "poor outcome" group (see Chapter 2), 
with special reference to the presence of a surgical correctable dominant stricture of 
the extrahepatic bile ducts. 
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3.3. Results 
The cholangiographic findings in the thirty patients with PSC are shown in Table 3.1. 
Thirteen patients had diffuse stricturing involving the intra- and extrahepatic bile ducts. 
A dominant stricture was noted involving the hepatic bifurcation/common hepatic duct 
in six patients, common bile duct in six, and bifurcation and common bile duct in one 
patient. Of the thirteen patients with dominant extrahepatic strictures, ten however also 
had diffuse intrahepatic involvement. Four patients had stricturing confined to the 
intrahepatic ducts. 
Additional cholangiographic abnormalities recorded were distortion of the terminal 
portion of the pancreatic duct in six patients, a stricture of the CBD in relation to the 
cystic duct entry in eight, and a left sided cystic duct entry in nine patients. A focal 
stricture of the left hepatic duct with upstream dilatation was noted on the 
cholangiogram of one of the two patients who was found to have a cholangiocarcinoma 
(Figure 3.2). 
Patient outcome in relation to the pattern of bile duct involvement is shown in Table 
3.2. There was no significant difference in the distribution of strictures in the two 
outcome groups. In particular, the presence of a dominant stricture involving the 
extrahepatic bile ducts did not correlate with an adverse prognosis. 
3.4. Discussion 
The radiologic appearances of PSC are characteristic. The intra- and extrahepatic bile 
ducts are involved to a variable degree, with multiple strictures and areas of relative 
dilatation giving a "beaded appearance" .1•2 "Pseudodiverticulae" of the bile ducts are 
highly suggestive but not pathognomonic of PSC. 4 The observation that some patients 
with PSC show abnormalities in the pancreatic ductal system has not been shown to be 
more than coincidence. 2•5 We have confirmed the previous observation by Pitt et al. 6 
of the terminal pancreatic duct being "pulled up" in approximately one third of 
cholangiograms reviewed. These changes presumably represent pancreatic duct 
distortion produced by fibrotic stricturing of the CBD. Another common and 
interesting finding was the presence of a dominant stricture of the CBD at the site of 
the cystic duct entry, and a left sided cystic duct entry, the latter which is also more 
prevalent in patients with CBD stones. 7 The significance of this finding remains 
obscure. 
Cholangiography was unhelpful in predicting patient outcome. We found no 
correlation between the distribution or severity of strictures at presentation (including 
the presence of a dominant stricture), and patient outcome. Of the studies on the 
natural history of PSC using multivariate analysis, only the one by Herrman et al. 
8 
found the site of biliary involvement to be of prognostic significance. In that study 
combined intra- and extrahepatic duct disease was found to be associated with a worse 
prognosis than intrahepatic duct disease alone. More recently, Craig et al. 
9 studied 
cholangiograms in 129 patients with PSC to determine if there was a correlation 
between any of the findings and the prognosis of the disease. The grade, length, and 
extent of strictures, the degree of bile duct dilatation, and the distribution of lesions 
were evaluated. Using univariate analysis, survival curves were generated to test the 
association of these radiological findings with subsequent survival. High-grade 
strictures and diffuse strictures of the intrahepatic ducts were found to be indicators of a 
poor prognosis. Interestingly, high-grade strictures of the extrahepatic ducts were not a 
significant predictor of poor outcome. 
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PSC essentially affects the biliary system in a diffuse manner. Dominant strictures of 
the extrahepatic bile ducts do not appear to carry special prognostic significance. 
Furthermore, there is often associated diffuse severe involvement of the intrahepatic 
bile ducts in these patients. There thus seems to be little justification for attempting to 
correct such dominant strictures surgically (see Chapter 4). 
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Figure 3.1 ERC of a patient with PSC demonstrating a "dominant stricture" 
involving the distal CBD (large arrow). The terminal portion of the 
pancreatic duct appears to be "pulled up" by the strictured CBD (small 
arrow). This patient remained minimally symptomatic for nine years. 
Table 3.1 Cholangiographic findings in 30 patients with PSC 
Pattern of bile duct involvement: 
1. Diffuse intra- and extrahepatic 13 
2. Dominant stricture 
a. Bifurcation/CHD* 6(5) 
b. CBD** 6(5) 
c. Bifurcation and CBD 1 (0) 
3. Intrahepatic only 4 
Other associated abnormalities: 
Pancreatic duct distorted 
Stricture related to cystic 
duct entry 
Left sided cystic duct entry 
6 
8 
9 
*CHD, common hepatic duct **CBD, common bile duct 
( ) = With associated diffuse intrahepatic disease 
30 
31 
Figure 3.2 ERC of a patient with cholangiocarcinoma complicating primary 
sclerosing cholangitis. A tight focal stricture of the left intrahepatic 
duct is evident with marked upstream biliary dilatation (arrow). 
TABLE 3.2 Cholangiographic findings in "good outcome" and "poor outcome" 
groups. 
Good outcome Poor outcome 
(n=20) (n=7) 
Biliary involvement: 
1. Diffuse intra- and extrahepatic 9 2 
2. Dominant stricture 
a. Bifurcation/CHO 2(0) 3(2) 
b.CBD 4(1) 2(2) 
c. Bifurcation and CBD 1(1) 
3. Intrahepatic only 4 
( ) = Biliary surgery 
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CHAYfER 4: SURGERY FOR PRIMARY SCLEROSING CHOLANGITIS 
4.1. Introduction 
Medical therapy of primary sclerosing cholangitis (PSC) remains unsatisfactory and 
surgical options are controversial. Biliary decompression for selected patients with 
PSC has been advocated by a number of surgical centres. 1•2 Unfortunately, the 
absence of prospective controlled data makes it impossible to totally assess the impact 
such surgery has had on the natural history of PSC. More recently, liver 
transplantation has been recommended as the therapy of choice for patients with end-
stage liver disease due to PSC. 3 Although early patient survival is now excellent, 4•5 
the ultimate effectiveness and safety of liver transplantation for PSC is incompletely 
understood. This study reviews the Cape Town experience with biliary surgery and 
transplantation for PSC during the past decade. 
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4.2. Patients and methods 
Six patients who had undergone biliary drainage operations for PSC in Cape Town 
between 1981 and 1988 were analysed and their outcome determined. The diagnosis 
was based on the clinical presentation, biochemical profile, and radiological features 
with confirmatory operative and histological findings in all patients. Surgical 
intervention in all six patients was indicated by progressive jaundice, with recurrent 
episodes of cholangitis in one patient. 
The details of the operative technique employed in Cape Town have been described 
elsewhere, 6 and are summarised here. Exploratory laparotomy was performed with 
liver biopsy and exposure of the biliary tree. The gallbladder was removed, the 
strictured extrahepatic bile duct opened, and multiple biopsy specimens taken to 
exclude cholangiocarcinoma. Intra-operative dilatation of all accessible intrahepatic 
duct strictures was performed using interventional radiological techniques. Following 
this, permanent transhepatic stenting was performed by placing a U-tube with or 
without a hepaticojejunostsomy (4 patients) or choledochojejunostomy (1 patient). A 
jejunal access loop was constructed in order to facilitate repeated post-operative 
percutaneous Grunzig balloon dilatations of the intrahepatic ducts, where necessary. 
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Two patients underwent orthotopic liver transplantation for end-stage liver disease due 
to PSC between 1988 and 1991. The biliary anastomosis was constructed via Roux-Y 
choledochojejunostomy in both recipients. Their clinical features and outcome are 
described. 
4.3. Results 
Six patients (three males, median age 38 years, range 24 - 49 years) underwent biliary 
drainage and duct dilatation(s) (Table 4.1). Four patients had associated IBD 
(ulcerative colitis 3, Crohn's disease 1). Median duration of symptoms before 
operation was 14 months (range 2 months - 4 years), and the mean serum bilirubin 
level at the time of surgery was 203 µmol/1 (range 48 - 444). A dominant biliary 
stricture was present involving the distal common bile duct (CBD) in three patients, the 
hepatic duct bifurcation in two patients, and the bifurcation and CBD in one patient. 
However, associated diffuse stricturing of the intrahepatic ducts was present in all but 
one patient. Wedge liver biopsy showed stage 2 histology in one patient, stage 3 
histology in two patients, and stage 4 histology in three patients. The patients were 
followed post-operatively for a median duration of 4.5 years (range 9 months - 9 
years). During this period two patients developed worsening symptoms related to 
progressive liver disease and four patients died (one from cholangiocarcinoma). 
Although there was an initial improvement in the serum bilirubin levels following 
surgery, obstructive jaundice recurred in all patients after a median follow-up of 10 
r 
months (range 7 to 30 months). No patient from the surgical group has subsequently 
undergone liver transplantation. 
Two patients underwent orthotopic liver transplantation for end-stage liver disease due 
to PSC. The first patient was a 36 year old male who initially presented with variceal 
bleeding, and was found to have biliary cirrhosis secondary to PSC. His post-operative 
course was complicated by recurrent attacks of bacterial cholangitis necessitating 
refashioning of the biliary anastomosis. The second patient was a 30 year old female 
with progressive jaundice, pruritus and fatigue due to advanced PSC. She had 
previously undergone panproctocolectomy for severe ulcerative colitis, as well as 
drainage of a hepatic abscess during pregnancy. Her post-operative course was 
complicated by cytomegalovirus hepatitis and ductopaenic rejection requiring FK 506 
immunosuppressive therapy. Both patients were alive with functioning grafts at seven 
and fourteen months respectively. 
4.4. Discussion 
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A variety of operations have been proposed in order to facilitate biliary drainage in 
patients with PSC. Historically, operative dilatation of the major bile ducts was 
performed with prolonged external T-tube drainage. Unfortunately, the results with 
this operation were poor. 7 This led some surgeons to institute a more aggressive 
approach at biliary decompression in selected patients with PSC. Cameron et al. 1 
advocated resection of the hepatic duct bifurcation and dilatation of intrahepatic ducts 
followed by prolonged transhepatic stenting. Favourable results were reported in non-
cirrhotic patients with dominant strictures at the hepatic duct bifurcation. 1 A simpler 
procedure was employed in Cape Town. This entailed biliary-enteric drainage of 
extrahepatic strictures with operative and, where necessary, repeated postoperative 
percutaneous dilatation of intrahepatic strictures with invasive radiological techniques. 6 
Although there was temporary relief of jaundice and pruritus in some patients, ultimate 
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outcome was not improved. The unfavourable experience m Cape Town can be 
explained by advanced chronic liver disease and associated diffuse intrahepatic 
stricturing in the patients operated on. Although patient numbers were small, it is felt 
that ductal surgery is not indicated in this subgroup, even in the presence of a surgical 
correctable stricture. The favourable results with biliary surgery reported by others 
may relate to patients being operated on at an earlier stage of the disease. However, it 
is unlikely that the natural history of this diffuse and progressive disease is altered by 
surgical intervention. Furthermore, these patients are at an increased risk for the 
development of bacterial cholangitis, 3 and future liver transplantation may be 
compromised. 8 It may be better to intervene endoscopically if possible, and to 
temporise until the patient becomes a candidate for liver transplantation. 9•10 
Liver transplantation is now regarded by many as the therapy of choice for patients 
with end-stage liver disease due to PSC. 3•11 Good transplant centres report survival 
rates of over 85 per cent at three years. 4•5 There are however several considerations 
(apart from variability of disease progression and prior biliary surgery) when selecting 
PSC patients for liver transplantation. These include the frequent fibrotic involvement 
of the extrahepatic ducts (necessitating choledochojejunostomy) , previous operations for 
IBD, and the unpredictable development of cholangiocarcinoma. 8 The ultimate 
effectiveness of liver transplantation for PSC is incompletely understood. There is a 
high complication rate following transplantation for PSC, and the retransplantation rate 
is increased. 12 Diffuse biliary stricturing has been found to occur more frequently in 
PSC patients undergoing liver transplantation. 13 While these findings suggest 
recurrence of PSC, there may be other factors such as reflux cholangitis (related to the 
choledochojejunostomy) and chronic rejection. 3 Our one transplant recipient required 
refashioning of the biliary anastomosis and the other recipient developed ductopaenic 
rejection requiring FK 506, both recognised complications of transplantation for this 
disorder. 13 • 14 
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CHAPTER 5: ASYMPTOMATIC PRIMARY SCLEROSING CHOLANGITIS 
IN ASSOCIATION WITH INFLAMMATORY BOWEL DISEASE 
5.1. Introduction 
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The widespread availability of endoscopic retrograde cholangiography (ERC) has led to 
a greater number of patients with primary sclerosing cholangitis (PSC) being diagnosed 
at an early asymptomatic stage. The diagnosis is made incidentally when a persistently 
raised alkaline phosphatase is discovered, usually in a patient with ulcerative colitis. 1 
Liver biopsy may be entirely normal or show portal inflammation, a histological 
picture previously termed "pericholangitis". 2•3 There has been controversy as to the 
proportion of asymptomatic patients who will progress, and the rate of progression to 
symptomatic chronic liver disease and liver failure. This is of importance in deciding 
whether asymptomatic patients should be offered entry into clinical trials of remittive 
drugs. Prognostic indices are applicable to patients with clinically symptomatic disease 
but are of limited use in the subpopulation identified by incidental biochemical results. 
5.2. Patients and methods 
All patients with asymptomatic PSC seen at the Inflammatory Bowel Disease (IBD) 
Clinic in Cape Town between January 1975 and December 1991 were studied. The 
diagnosis was suspected by the finding of a persistently raised alkaline phosphatase (to 
more than twice the normal level) in a patient with IBD, and confirmed at ERC. 
Patients were followed prospectively and monitored for biochemical or clinical 
evidence of disease progression. The cholangiograms were reviewed and the 
distribution and severity of biliary strictures were recorded. 
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5.3. Results 
Nine patients, five males median age 34 years (range 18 - 53 years), were identified 
(Table 5.1). At diagnosis patients had a mean (SEM) serum alkaline phosphatase of 
300 ( 11. 9) iu/1 (normal 30 - 115) and serum aspartate transaminase of 54. 2 (5. 5) iu/1 
(normal O - 40). Associated IBD comprised ulcerative colitis (7), Crohn' s ileocolitis 
(1), and unclassified colitis (1). Associated ulcerative colitis was invariably extensive 
but symptomatically mild. One patient required panproctocolectomy for colonic 
dysplasia. The frequency of asymptomatic PSC in patients with ulcerative colitis was 
approximately 0.6 per cent. Mean duration of IBD before diagnosis of PSC was seven 
years (range 1 - 24 years). ERC demonstrated minimal stricturing confined to the 
intrahepatic biliary tree in three patients , diffuse stricturing affecting both the intra-
and extrahepatic bile ducts in five patients (Figure 5.1), and a dominant stricture 
involving the common hepatic duct in one patient. Liver biopsy was performed in two 
patients. Histology showed mild condensation of periportal fibrous tissue in the one 
patient and "pericholangitis" in the other patient. None of these patients developed 
overt liver disease during a mean follow-up period of 5.3 years (range 1 - 12 years). 
Serum bilirubin levels became mildly elevated (to 22µmol/l and 33µmol/l respectively) 
in two patients. 
5.4. Discussion 
Some patients with PSC have no symptoms referrable to their liver disease. The 
proportion of asymptomatic patients in published series varies from 16 - 25 per cent. 4-6 
In the natural history study performed in Cape Town, 20 per cent of the PSC patients 
were asymptomatic at presentation (see Chapter 2). The frequent detection of PSC 
patients during an asymptomatic phase relates to the widespread availability of ERC 
together with an increased awareness of the association of PSC with IBD. The 
diagnosis is suspected by the finding of a persistently raised alkaline phosphatase in a 
patient with ulcerative colitis and confirmed at ERC. 7 Previously the term 
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"pericholangitis" was synonymous with asymptomatic involvement of the liver in 
patients with IBD. 2,3 However, it has become clear that most patients with histological 
pericholangitis, defined as an inflammatory portal reaction with periductular 
inflammation and fibrosis, will have cholangiographic appearances of PSC. 8 A 
minority of patients with ulcerative colitis will have persistently abnormal liver function 
tests together with histological appearances such as concentric fibrosis , but have normal 
bile ducts at cholangiography. The term "small duct primary sclerosing cholangitis" 
has been proposed to replace the term "pericholangitis" in this group of patients, as the 
evidence suggests that these conditions are all part of the same disease spectrum. 9 
The outcome for patients with asymptomatic PSC has not been clearly established. 
Chapman et al. 10 initially suggested that PSC may remain asymptomatic for many 
years. They reported on three cases of asymptomatic PSC with extensive 
cholangiographic abnormalities who remained well for up to 15 years. Follow-up liver 
biopsy in two showed no evidence of histological progression. Heltzberg et az.6 
described 13 PSC patients who were asymptomatic at presentation and remained so 
during a mean follow-up period of 56 months. In addition, Aadland et al. 11 reported 
that 27 asymptomatic or minimally symptomatic patients followed for a mean of 4.4 
years showed no evidence of disease progression. This is in contrast to findings by 
Porayko et al. 12 who found that 76 per cent of 45 asymptomatic patients had clinical or 
laboratory evidence of disease progression during a median follow-up of 75 months and 
31 per cent developed liver failure resulting in death or referral for liver 
transplantation. These results were in agreement with those of Herrman et aZ. 13 who 
reported on 14 asymptomatic patients; nine (64 per cent) showed clinical progression 
over a mean follow-up period of three years. 
This study shows that the outcome for asymptomatic PSC patients is clearly better than 
for those who are already symptomatic. 14 This favourable outcome can be explained 
by the design of the study. Patients attending the IBD Clinic in Cape Town were 
actively screened for abnormal liver function tests and then submitted for ERC 
examination. Thus, asymptomatic patients were detected at an earlier stage in their 
disease process. Of interest however was that cholangiography in these patients did not 
necessarily reflect early disease; some patients had diffuse severe stricturing of the 
biliary tree, and one patient had a dominant stricture of the extrahepatic bile duct. 
Inclusion of these asymptomatic patients in clinical trials of drugs designed to reduce 
disease progression may falsely skew overall results. They should therefore be 
stratified prior to entry into such trials. It seems likely however that many of these 
patients will eventually progress to symptomatic chronic liver disease. Further follow-
up of this important subset of patients is thus needed. 
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Figure 5.1 ERC of patient 4 showing classical changes of primary sclerosing 
cholangitis with diffuse stricturing affecting both the intra- and 
extrahepatic bile ducts. This patient has remained completely 
asymptomatic for twelve years. 
CHAPTER 6: MALIGNANT CHOLANGIOPATHY MIMICKING PRIMARY 
SCLEROSING CHOLANGITIS 
6.1. Introduction 
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Hepatobiliary infiltration with neoplastic/malignant cells may produce a clinical and 
cholangiographic picture similar to that of primary sclerosing cholangitis (PSC). This 
may be due to biliary compression by tumour cells, or due to bile duct injury with 
scarring. This chapter documents three cases of malignant obstructive cholangiopathy 
seen in Cape Town, with a review of the literature. Malignant infiltration of the 
hepatobiliary system should be considered in the differential diagnosis of PSC where 
atypical presentations are noted. 
6.2. Case reports 
6.2.1. Idiopathic hypereosinophilic syndrome 
A 16 year old boy was referred for investigation of a pyrexia of unknown origin 
associated with eosinophilia and abnormal liver tests. There was a five week history of 
a febrile illness with associated lethargy, backache, dyspepsia, intermittent diarrhoea, 
joint pains and weight loss. Clinically he was ill and pyrexial with mild 
lymphadenopathy and jaundice. There was a 3cm firm hepatomegaly (15cm span) and 
a 2cm splenomegaly. Colonoscopy demonstrated friable oedematous mucosa extending 
from the rectum to proximal transverse colon and histology revealed non-specific colitis 
with incipient crypt abscesses. Special investigations revealed anaemia, leucocytosis 
with a marked eosinophilia of 28 OOO/mm3, and biochemical tests confirmed severe 
cholestasis. Anti-nuclear and anti-smooth muscle antibodies were present in low titre. 
Repeated blood, urine and stool cultures, and serology for all potentially relevant 
infections, including human immunodeficiency virus (HIV), were negative. Computed 
tomography (CT) showed an enlarged liver with features suggestive of periportal 
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oedema, but no intrahepatic biliary dilatation. Endoscopic retrograde cholangiography 
(ERC) demonstrated marked irregularity of the intrahepatic ducts suggestive of PSC 
(Figure 6.1). Initial liver histology demonstrated eosinophilic infiltration around portal 
tracts and the bile ducts, but no periductal fibrosis to suggest PSC. The initial clinical 
diagnosis was considered to be idiopathic hypereosinophilic syndrome with 
gastrointestinal involvement and obstructive cholangiopathy. The patient failed to 
respond satisfactory to steroid therapy, and his course was marked by progressive 
eosinophilia with recurrent fever, vasculitic skin lesions, worsening diarrhoea and 
mental confusion. Induction chemotherapy as for eosinophilic leukaemia was 
commenced, but this was complicated by cerebellar toxicity and terminal 
gastrointestinal haemorrhage. At postmortem, histology revealed dense circumferential 
fibrosis of large bile ducts, hepatic fibrosis and cholestasis. There was a chronic 
inflammatory cell infiltrate of the colon with scarring, but no eosinophils were seen. 
Review of marrow trephine biopsies provided convincing evidence of evolution into 
eosinophilic leukaemia. 
6.2.2. Langerhans-cell histiocytosis 
A 10 year old boy presented with progressive pulmonary disease associated with 
chronic liver disease and portal hypertension. Hepatosplenomegaly had been noted 4 
years previously and was thought to be compatible with congenital hepatic fibrosis after 
examination of liver histology. This young patient developed progressive splenomegaly 
and pancytopaenia over the next three years. Bone marrow trephine biopsies were 
consistent with hypersplenism. Two years after initial presentation, he developed a 
persistent cough, and chest radiography demonstrated bilateral infiltrates. Atypical 
mycobacteria were cultured from sputa, but response to antituberculous therapy was 
poor. A few months before admission he developed progressive fatigue, weight loss, 
jaundice, steatorrhoea and worsening cough. Clinically, he appeared chronically ill 
with pallor and jaundice. A persistent low grade fever was noted. Digital clubbing, 
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generalised lymphadenopathy and spider naevi were also documented. Chest 
auscultation revealed soft basal crackles. A shrunken liver with a total vertical span of 
8cm, minimal ascites and massive splenomegaly, which extended into the right iliac 
fossa, were present. Stools tested positive for occult blood. Special investigations 
revealed pancytopaenia and marked cholestasis; steatorrhoea was confirmed on a three 
day stool collection. There was no biochemical evidence of diabetes insipidus. Lung 
functions demonstrated non-obstructive reduction in volumes with a decreased transfer 
factor. Sputum examination was unhelpful. Chest radiography showed diffuse 
inhomogeneous opacification with small cystic changes in both lungs and a basal 
honeycomb pattern. No lytic bone lesions were seen. Abdominal CT demonstrated 
massive splenomegaly, a small lobulated liver and ascites. No biliary duct dilatation or 
focal hepatic lesions were seen. He was subjected to open lung biopsy and repeat liver 
biopsy. Histopathology revealed pulmonary Langerhans-cell histiocytosis with 
characteristic markers, including T6 antigen and S-100 protein. Liver histology 
showed extrahepatic cholestasis and septal fibrosis but no evidence of active 
histiocytosis. ERC was not performed as his immediate post-operative course was 
complicated by a major variceal bleed requiring urgent sclerotherapy. He deteriorated 
rapidly and died shortly thereafter. 
6.2.3. Metastatic ovarian adenocarcinoma 
A 39 year old woman was referred with a diagnosis of end-stage PSC for liver 
transplantation. She had been well until 2 years before admission when she had 
experienced severe left iliac fossa pain. Hysterectomy and bilateral salpingo-
oophorectomy were performed for a fibroid uterus and what was considered to be 
bilateral cystadenomas of the ovaries. Nine months prior to admission at Groote 
Schuur Hospital she developed worsening right upper quadrant pain with itching, 
nausea, protracted vomiting and a 20kg weight loss. ERCP at another hospital was 
suggestive of PSC. Clinically, she was ill and jaundiced with profuse vomiting. There 
was foetor hepaticus with asterixis. A tender 3cm hepatomegaly (span of 14cm) was 
noted but the spleen was impalpable. Biochemistry showed severe cholestasis. Viral 
serology, autoantibodies and tumor markers were negative. CT revealed a normal 
sized liver with multiple low density tubular structures within it, but no mass lesions. 
There was mild dilatation of the extrahepatic bile duct. Minimal ascites was 
demonstrated and there was no evidence of adenopathy. ERC demonstrated diffuse 
narrowing and irregularity of the intrahepatic bile ducts with involvement of the hepatic 
duct bifurcation. The extrahepatic bile duct was not involved (Figure 6.2). At 
laparotomy, metastatic cystadenocarcinoma with gross involvement of the liver, 
mesentery, omen tum and porta hepatis was present. Tumour cells showed strong 
positivity for carcino-embryonal antigen. Review of the initial ovarian histology 
confirmed mucinous cystadenocarcinoma. 
6.3. Discussion 
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Malignant hepatobiliary infiltration may produce a cholangiographic picture similar to 
that of primary sclerosing cholangitis (PSC). Cholangiocarcinoma is the tumour that is 
most commonly mistaken for PSC. This tumour may indeed complicate PSC in five to 
ten per cent of patients, and both conditions may present simultaneously. 1 
Cholangiocarcinoma complicating PSC is heralded by rapid clinical deterioration with 
progressive jaundice, weight loss and abdominal discomfort. The tumour is usually 
detected at an advanced stage and the prognosis is poor. 2 
This chapter describes three cases of malignant obstructive cholangiopathy mimicking 
PSC. 3 The first report describes a 16 year old boy with idiopathic hypereosinophilic 
syndrome (HES) who presented with colitis and obstructive cholangiopathy, closely 
resembling PSC with associated ulcerative colitis. ERC demonstrated marked 
irregularity of the intrahepatic bile ducts. Initial eosinophilic infiltration of the liver 
was followed by fibrotic scarring involving both intra- and extrahepatic bile ducts. 
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Post-mortem histology of the colon favoured chronic idiopathic inflammatory bowel 
disease rather than eosinophilic gastroenteritis, but the picture may have been modified 
by prior chemotherapy. HES is considered to be a multisystem idiopathic disorder 
characterised by prolonged eosinophilia with organ dysfunction. Hepatic involvement 
occurs in approximately 30 per cent of cases, and usually consists of periportal 
infiltration by eosinophils. 4 However, Scheurlen et al. 5 have recently reported a case 
of HES with radiologically and histologically confirmed involvement of the bile ducts 
(Table 6.1). Their patient had endoscopically proven colitis with extreme eosinophilia, 
and went on to develop obstructive cholangiopathy and recurrent angioedoma. 
Subsequently a good response to hydroxyurea therapy was documented. Although 
eosinophilia has been reported in association with PSC, 6 the extreme eosinophilia with 
organ dysfunction pointed to the correct diagnosis, as in this patient. 
The second report describes a 10 year old boy with Langerhans-cell histiocytosis (LCH, 
histiocytosis X) who presented with hepatic fibrosis, and later developed active lung 
disease with progressive hepatobiliary involvement. Although ERC was not performed 
in this instance, liver biopsy demonstrated involvement of intrahepatic intralobular bile 
ducts together with histological evidence of extrahepatic large duct obstruction. LCH 
is characterised by infiltration of various organs by histiocytes or dendritic cells 
recognised by specific Birbeck granules on electron microscopy or T6 antigenic 
markers. 7•8 The course is highly variable with remissions, but residual disability may 
result from fibrotic scarring. Thompson et al. 9 reported on three patients with biopsy 
proven histiocytosis who developed a clinical and pathological picture compatible with 
PSC (Table 6.1). They showed that the abnormal cell types may be absent from liver 
biopsy specimens which may merely show fibrotic scarring. The authors concluded 
(probably erroneously) that histiocytosis may be an underlying cause of PSC in some 
instances. Case reports of portal hypertension in infants and children with histiocytosis 
during the 1970's (ERC examinations were not performed) probably described the 
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same condition. 10 In this case the young age at presentation and the development of 
active lung disease were against the diagnosis of PSC. 
The third report describes a 39 year old woman with metastatic ovarian 
adenocarcinoma who was thought to have advanced PSC possibly complicated by 
cholangiocarcinoma. ERC showed diffuse involvement of the intrahepatic biliary tree 
with multifocal strictures, and involvement of the hepatic duct bifurcation. The 
extrahepatic ducts were uninvolved, however. Despite a thorough workup, no evidence 
of malignancy could be found prior to laparotomy for liver transplantation. Vilgrain et 
al. 11 recently reported on three patients with metastatic adenocarcinoma who presented 
with obstructive cholangiopathy (Table 6.1). Cholangiography in all cases showed 
displacement and distortion of intrahepatic bile ducts with strictures simulating PSC. 
In two patients, histological examination showed periductal fibrosis or inflammation. 
Our patient did in fact have an atypical course for PSC characterised by worsening 
right upper quadrant pain, severe vomiting and rapid weight loss. This clinical 
presentation could be compatible with cholangiocarcinoma complicating PSC. The lack 
of extrahepatic duct involvement was against the diagnosis of PSC, although by no 
means excluded it. The initial pathological diagnosis of benign cystadenomas of the 
ovaries two years prior to this illness at another institution was obviously misleading. 
A critical review of the ovarian histology should have led to earlier diagnosis in this 
instance. 
The characteristic cholangiographic findings in PSC consist of multifocal strictures 
involving intra- and extrahepatic bile ducts with focal areas of dilatation, giving a so-
called "beaded appearance" .12•13 This picture may however be closely mimicked by 
malignant hepatobiliary infiltration due to HES, LCH or metastatic adenocarcinoma. 
Other malignant tumours that may rarely produce a similar cholangiographic picture 
include lymphoma, 14 carcinoma of the gallbladder15 and prostate, 16 and squamous 
carcinoma of the liver. 17 The pathogenesis of the cholangiographic findings may be 
due to biliary distortion by tumor cells, or else due to bile duct injury with resultant 
scarring. Inflammatory mediators released by eosinophils (eg. major basic protein, 
eosinophil cationic protein) or histiocytes may have contributed to the biliary injury and 
scarring seen in these patients. 18 HES and LCH both follow an unpredictable course 
with relapses and remissions. The abnormal cell types may thus be absent from a liver 
biopsy specimen which may then show only fibrotic scarring. It may be necessary to 
biopsy other involved organs, such as bone marrow or lung, in order to diagnose these 
malignant disorders. 
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The typical patient with PSC is a young male who has concurrent inflammatory bowel 
disease, usually ulcerative colitis. 19 The clinical picture is generally that of insidious 
cholestasis which is slowly progressive, unless complicated by the development of 
cholangiocarcinoma. Many disorders may mimick PSC, including malignant 
hepatobiliary infiltration other than cholangiocarcinoma. PSC is a diagnosis that can be 
made with confidence in the appropriate clinical setting, but remains one of exclusion. 
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Figure 6.1 ERC of case 1 demonstrating marked irregularity of the intrahepatic 
bile ducts suggestive of primary sclerosing cholangitis. 
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Figure 6.2 ERC of case 3 demonstrating diffuse narrowing and irregularity of the 
intrahepatic bile ducts with involvement of the hepatic duct 
bifurcation. The extrahepatic duct was however not involved. 
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CHAPTER 7: REVIEW AND CONCLUSIONS 
7.1. Natural history 
The last decade has seen major advances in the understanding of many aspects of 
primary sclerosing cholangitis (PSC). 1 PSC is diagnosed much more frequently with 
the advent of ERCP, and is no longer considered to be a rare disease. 2 The diagnostic 
features of PSC have been described in more detail, 3•4 and its natural history better 
defined. 5,6 As the finding of associated ulcerative colitis is an important confirming 
point in the diagnosis, all patients with newly diagnosed PSC should undergo 
colonoscopy, even in the absence of any bowel symptoms. Patients with PSC who 
have a serum bilirubin level persistently raised above 80µmol/l are likely to have a 
poor outcome, and should be referred to a Liver Centre for consideration for suitability 
for, and assessment of timing of liver transplantation. Although most symptomatic 
patients will progress, the clinical course of PSC is highly variable and a few patients 
appear to follow a genuinely benign course. 7 This variability and unpredictability may 
relate to factors in addition to progressive fibrotic biliary stricturing, such as recurrent 
bacterial cholangitis, concurrent biliary sludge or stones, toxic effects of retained bile 
salts, and the development of cholangiocarcinoma. Furthermore, it has been our 
experience that the clinical condition of young women with PSC deteriorates markedly 
during pregnancy with increasing jaundice and episodes of sepsis. Asymptomatic PSC 
patients, on the other hand, may experience many years of quiescence despite markedly 
abnormal cholestatic liver function tests and diffuse extensive biliary stricturing 
demonstrated at cholangiography. 8-10 These patients may have a milder form of the 
disease. Alternatively, PSC patients may have a long asymptomatic lag phase followed 
by a phase of progressive worsening symptoms, somewhat analogous to primary biliary 
cirrhosis. 11 Clearly long-term follow-up studies of asymptomatic PSC patients are 
needed in order to resolve this important issue. 
62 
7 .2. Aetiology 
Although the aetiology of PSC remains unknown, genetic and immunological factors 
appear important. In this context, the close association of HLA DRw52a with the 
susceptibility to develop PSC is intriguing. 12 HLA DRw52a encodes a protein with a 
leucine residue at position 38 of the DR B chain. 13 Position 38 is thought to be located 
in the base of the peptide binding groove of the HLA DR molecule, and it is possible 
that amino acid substitutions at this site could affect the affinity of peptide binding or 
DR peptide complex interactions with relevant T cell receptors. The alternative amino 
acids which can occupy position 38 of DR 3 are alanine and valine, and it would 
appear that the presence of alanine, associated with HLA DRw53, confers protection 
from the risk of developing PSC. 13 The close association of HLA class II molecules 
with PSC suggests that these molecules may play an important role in the regulation of 
the abnormal immune response which underlies this disease. However, the antigen 
presented by the HLA molecule remains elusive. 
Studies on auto-immune mechanisms in PSC have not yet shown definitive results 
however, and an infective aetiology could still underlie the pathogenesis of PSC. The 
HLA data described above could represent susceptibility to an infection rather than 
variant immune mechanisms. The typical fluctuating clinical course of PSC could be 
considered as compatible with a chronic re-activating viral infection such as 
cytomegalovirus (CMV). Infection of the gallbladder by CMV is well documented. 14 
Since 1986 infection of the bile ducts with CMV has been increasingly recognised in 
patients with the acquired immunodeficiency syndrome (AIDS). The development of 
sclerosing cholangitis in many of these patients ("AIDS sclerosing cholangitis"), with 
cholangiographic features very similar to classical idiopathic PSC is of great interest. 15 
Further evidence of CMV-induced biliary damage is the high incidence of a chronic 
form of hepatic rejection characterised by loss of intralobular and small bile ducts 
("vanishing bile ducts") in patients following orthotopic liver transplantation 
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complicated by hepatic CMV infection. 16 Direct evidence of CMV infection in PSC 
came from a study by Mason et al. 17 which detected CMV-DNA in the liver tissue of 
7/7 PSC patients but in only 5/20 controls. However, Mehal et al. 18 were unable to 
confirm these findings using a highly sensitive polymerase chain reaction (PCR) based 
assay for CMV-DNA. They studied 37 PSC and 19 control samples of formalin-fixed 
and paraffin-embedded hepatobiliary tissue. The lack of CMV-DNA in 35 of 36 PSC 
samples amplified was felt to effectively rule out any significant CMV reactivation in 
their group and suggested that CMV replication and reactivation were not responsible 
for the progression of PSC. Personal communications with Mason subsequently 
suggested methodological difficulties with the published abstract (S.C. Robson; Nov 
1992, AASLD). 
In Cape Town, we have been collecting samples of serum, urine and tissue from all 
PSC patients seen. These samples have been stored frozen at -70° and in liquid 
nitrogen for future research into the genetic, immunologic and infective mechanisms 
underlying PSC. At present the bank of samples consists of serum (24 patients), urine 
(24 patients), liver biopsy specimens (16 patients), bile (4 patients), and large amounts 
of hepatobiliary tissue from transplanted PSC livers (3 patients). 
A critical issue in the understanding of the pathogenesis of PSC is the close association 
of this unusual disease with ulcerative colitis. A previously attractive hypothesis 
related this association to increased colonic mucosa! permeability in regions of high 
luminal concentrations of anaerobic bacteria (as may occur in chronic ulcerative 
colitis). Increased uptake of bacteria, bacterial products (endotoxin, peptidoglycan-
polysaccharide) or inflammatory mediators (interleukin-I, tumour necrosis factor) into 
the portal vein could lead to hepatobiliary injury in a genetically susceptible host. In 
this regard Lichtman et al. 19•20 recently reported on an experimental model of 
hepatobiliary inflammation associated with small intestinal overgrowth of anaerobic 
bacteria. Surgical creation of a self-filling blind loop in the jejunum of genetically 
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susceptible rats led to hepatomegaly, increased aspartate transaminase levels, increased 
bile flow, and chronic periportal inflammation characterised by mononuclear cells and 
occasional neutrophils surrounding bile ducts, proliferation of small bile ducts and 
fibrosis. Cholangiography demonstrated tortuosity and irregularity of the intrahepatic 
ducts, and ectasia of the extrahepatic bile duct. Inbred rat strains exibited differential 
susceptibility to hepatobiliary inflammation: Lewis rats developed lesions two to four 
weeks after creation of a blind loop, Wister rats after twelve weeks, and Buffalo and 
Fischer (MHC compatible with Lewis) rats failed to develop lesions in up to six months 
of observation despite equal luminal bacterial concentrations. Inflammation apeared to 
be the result of systemic absorption of peptidoglycan-polysaccharide polymers from 
intestinal anaerobic bacteria. 21 A negative point to this hypothesis is the lack of effect 
of colectomy on the natural history of PSC in patients with this disease. 22 
7 .3. Antibiotic therapy 
In the abovementioned experimental model of small bowel bacterial overgrowth 
hepatobiliary inflammation can be prevented by metronidazole, tetracycline (but not 
gentamicin or polymixin B)23 and mutanolysin, 24 an enzyme that degrades 
peptidoglycan. Like PSC, the experimental hepatobiliary inflammation did not respond 
to prednisone, ursodeoxycholic acid, methotexate or cyclosporine A. Long term 
antibiotic therapy has not been tested in PSC patients in a controlled fashion. Of 
anecdotal interest however is that two PSC patients followed in Cape Town have 
remained well on cyclical courses of co-trimoxazole (2 tablets bd for 5 days of the 
month) after five and nine years respectively (unpublished observation). Prophylactic 
antibiotic therapy was initially commenced as prophylactic therapy for recurrent bouts 
of bacterial cholangitis in the two patients. It is thus uncertain whether the possible 
beneficial effect of co-trimoxazole observed in these patients has been due to the 
prevention of further episodes of bacterial cholangitis or the treatment of an underlying 
pathogenetic mechanism of PSC. In the light of these findings a protocol for a 
proposed controlled trial of co-trimoxazole in the treatment of PSC in Cape Town has 
been drawn up (see Appendix A). Anticipated difficulties with such a trial include the 
long and unpredictable natural history of PSC and the relatively small number of PSC 
patients seen at only one Liver Centre, and discussions to extend the study to 
Johannesburg need to be continued. 
7 .4. Liver transplantation 
Currently orthotopic liver transplantation is the therapy of choice for patients with end-
stage liver disease due to PSC. 25•26 Currently in 1993 five patients with advanced PSC 
are awaiting liver transplantation in Cape Town and three patients have undergone this 
procedure. Although statistical survival models may be helpful, the decision regarding 
the selection and timing of therapeutic intervention with liver transplantation for PSC 
requires sound and individualised clinical judgement. 27 Palliative biliary drainage 
operations should be avoided in PSC patients as such surgery may compromise future 
liver transplantation. 26•28 Unfortunately, liver transplantation for PSC is fraught with 
problems including diffuse biliary stricturing and ductopaenic rejection, which appear 
to occur at a higher frequency in this condition.29-31 Ultimately more effective 
medical therapies and prophylactic measures are needed for this fascinating and 
enigmatic condition. 
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APPENDIX A: PROTOCOL FOR PROPOSED BACTRIM TRIAL 
A therapeutic trial to evaluate the efficacy of long term oral co-trimoxazole (Bactrim, 
RocheR) in the treatment of primary sclerosing cholangitis. 
Pricipal Investigator: E. Lemmer 
Associate Investigators: P.C. Bornman, S.C. Robson, J.P. Wright, J.E.J. Krige, A. 
Girdwood, H. Bloch. 
1. Introduction 
Primary sclerosing cholangitis (PSC) is an uncommon inflammatory disorder of 
unknown cause characterised by segmental or diffuse fibrosis of the hepatobiliary 
system. Although the natural history is variable and unpredictable, progression is 
usually relentless with the development of biliary cirrhosis, portal hypertension and 
liver failure. The strong association with idiopathic inflammatory bowel disease, 
especially ulcerative colitis, suggests a causal relationship. Both diseases may be the 
result of a persistently abnormal immune response to gut derived bacterial antigens. 
Theoretically, elimination of these bacterial antigens from the gut might interrupt this 
postulated pathogenic process. 
There is anecdotal evidence of a favorable response to the use of long term oral co-
trimoxazole (Bactrim, RocheR) in two patients with PSC who did not have recurrent 
bouts of fever (P.C. Bornman: personal communication). This form of therapy has 
been introduced in selected patients over the last 15 to 18 months with apparently 
favourable responses. To date however there have been no controlled studies 
examining the effect of antibiotics in patients with PSC. Tetracyclines have previously 
been found to be ineffective. Antibiotics have been used to treat episodes of bacterial 
cholangitis, or in prophylaxis for patients who have already experienced such insults. 
In this setting antibiotics may reduce the incidence of recurrent bacterial cholangitis but 
have no effect on slowing progression of the disease. In the uncontrolled studies cited, 
patients usually had advanced liver disease, and it is thus possible that only patients 
with irreversible end-stage liver disease were studied. 
The combination of trimethoprim and sulfamethoxazole (co-trimoxazole) results in 
antimicrobial synergism by sequential inhibition of a common biochemical pathway. 
Sulfamethoxazole exerts its antibacterial effect by competing with p-aminobenzoic acid 
(PABA) to prevent the formation of 7,8 - dihydropteroate (DHPA). Trimethoprim 
inhibits dihydrofolate reductase and thus inhibits the production of tetrahydrofolic acid 
from dihydrofolic acid (DHFA). Bacterial cells generally cannot absorb exogenous 
folates; thus they are unable to bypass the block created by trimethoprim and 
sulfamethoxazole. Mammalian cells are protected because they contain a different 
dihydrofolate reductase which is much less sensitive to trimethoprim, and absorb 
exogenous folate. 
Co-trimoxazole is active against a wide range of gram-negative enteric organisms, 
including E.coli, S.typhi, Shigella spp. and Enterobacter spp. Co-trimoxozale has been 
used in the treatment of bacterial gastroenteritis and also for prophylactic gut 
decontamination in neutropaenic patients. Theoretically prolonged treatment with co-
trimoxazole may be beneficial in patients with PSC by reducing the number of episodes 
of bacterial cholangitis. In addition, elimination of gut-derived bacterial antigens may 
affect the underlying pathogenetic process in this disorder. 
Bacteria may develop resistance to trimethoprim-sulfamethoxazole synergism. 
Mechanisms include (a) an altered dihydropteroate synthetase with a decreased affinity 
for sulfonamides and (b) an altered dihydrofolate reductase with a decreased affinity for 
trimethoprim. Both mechanisms may be plasmid - mediated. 
Co-trimoxazole toxicity is most frequently due to hypersensitivity reactions. 
Neutropaenia and thrombocytopaenia may occur. However, few instances of marrow 
depression secondary to the antifolate effect of trimethoprim have been reported. Such 
toxicity is theoretically reversible with folinic acid. 
The aim of this trial is to assess the efficacy of long term co-trimoxazole in the 
treatment of PSC. 
2. Objectives 
1. To determine the efficacy of long term oral Bactrim on improvement of symptoms 
and biochemical markers in patients with PSC. 
2. To assess the safety profile of prolonged treatment with Bactrim in patients with 
PSC. 
3. Trial design 
This is a therapeutic trial in which patients will be given treatment with co-trimoxazole 
for 6 months after which they will be followed on no treatment for another 6 months. 
4. Patients 
a. Inclusion criteria 
1. Patients with documented primary sclerosing cholangitis, based on cholangiographic 
findings, together with compatible clinical (eg. ulcerative colitis) and biochemical 
features. 
2. Symptomatic (patients with a predicted survival prognosis of greater than 1 year, 
and serum bilirubin less than 85 umol/litre. 
3. Patients aged between 18 and 70 years. 
4. Written or verbal (witnessed) informed consent. 
5. Patient is co-operative and can attend regular clinic visits. 
b. Exclusion criteria 
1. Patients with secondary sclerosing cholangitis or other potential causes of liver 
disease. 
2. Patients who have undergone prior surgery with biliary drainage. 
3. Patients with known drug allergy to sulphonamides or trimethoprim, or with G6PD 
deficiency. 
4. Patients who are unable to stop disallowed medication at or before the start of the 
trial (see below). 
5. Patients with advanced liver disease complicated by bleeding varices, ascites or 
hepatic encephalopathy. 
c. Number of patients 
15 consecutive evaluable patients with proven primary sclerosing cholangitis. 
5. Treatment 
a. Drugs, fonnulations and strengths 
Bactrim single strength (trimethoprim 80mg: sulfamethoxazole 400mg) will be supplied 
by Roche pharmaceuticals. 
b. Dosage regimen 
Patients will be treated with co-trimoxazole for 6 months after which they will be 
followed on no treatment for another 6 months. 
The two treatment regimen will be as follows: 
Group A: Bactrim 2 tablets b.d. x 4 weeks, then 
1 tablets daily for 5 months. 
After 26 weeks therapy will be stopped and patients will be followed for another 6 
months. 
c. Concomitant medication 
The following drugs must not be taken by, or administered to, the patient during the 
trial: 
Penicillamine, colchicine, methotrexate or other experimental therapies for PSC. 
However patients may be treated with drugs such as ursodeoxycholic acid (UDCA) and 
cholestyramine which modify bile acids. Antibiotics in conventional dosage and 
duration of therapy may be used for the treatment of episodes of presumed acute 
bacterial cholangitis which occur despite co-trimoxazole therapy. Drugs necessary for 
the treatment of associated inflammatory bowel disease ( eg corticosteroids, 
sulfasalazine) are allowed. However, immunosuppressive agents (eg azathioprine, 6-
mercaptopurine) may not be used. All concomitant medications taken during the trial 
must be recorded. 
6. Assessments/evaluatons 
A medical history will be taken and physical examination performed at entry; 
thereafter assessments/evaluations will be made at 4 weeks, 3 months, 6 months and 12 
months.. Pill counting wil be done as a check on compliance. A liver biopsy will be a 
prerequisite for entry into this trial. 
a. Clinical evaluation 
The following clinical parameters will be scored at each visit: 
i. pruritus 
ii. jaundice 
iii. fatigue 
iv. Right upper quadrant pain 
Scoring will be as follows: 
0 = Absent 
1 = Mild 
2 = Moderate 
3 = Severe 
4 = Very severe 
In addition the following will be recorded at each visit: 
i. Number of febrile episodes since last visit 
ii. Weight change since last visit 
iii.Degree of incapacitation during last month. 
At each visit the patient will complete a 10 cm visual analogue scale (VAS) indicating 
his / her general well being. The limits of this VAS are: "couldn't be worse" and 
"couldn't be better"! 
b. Laboratory analysis 
The following serum biochemical markers will specifically be recorded at each visit: 
i. Total bilirubin, direct bilirubin, alkaline phosphatase, AST, ALT, albumin. 
ii. Blood cultures when indicated. 
iii.Serum pIII peptide will be measured at week 0, 16 and 32 as a marker of 
fibrogenesis. 
c. Safety evaluations 
A full blood count will be done at each visit to monitor for the development of 
cytopaenias during therapy. Anaemia or thrombocytopaenia (eg. due to hypersplenism) 
is not a contraindication to entry into this study. 
7. Adverse experiences 
All adverse experiences reported during this clinical trial must be recorded by the 
investigator. Any patient who develops a serious adverse experience (eg. 
hypersensitivity reaction, cytopaenia) must immediately be withdrawn from the trial. 
8. Statistical analysis 
Calculation of the sample size is based on an expected 20 % decrease in serum bilirubin 
and pill peptide following treatment with co-trimoxazole (bilirubin mean/SD stable 
symptomatic PSC assumed 39/8.8, alpha=0.05, power=80%). The sample will 
consist of 15 consecutive patients who will act as their own controls. 
The primary efficacy parameters are: 
1. The number of patients showing a significant reduction of serum bilirubin and p III 
peptide at the end of treatment 
2. The number of patients discontinuing the trial prematurely because of lack of 
therapeutic effect. 
The secondary efficacy parameters are: 
1. Pruritus, jaundice, fatigue 
2. Febrile episodes, weight change, incapacitation 
3. Visual analogue scale 
All secondary efficacy parameters will be analysed in an explorative way. 
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